Clinical Trial

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-05-18; most recent amendment 2024-04-30.
Status change: Recruiting → Active, Not Recruiting 2024-04-30
Status change: Not Yet Recruiting → Recruiting 2023-05-31
Trial Details
NCT Number NCT05879744
Lead Sponsor Cullinan Therapeutics Inc.
Conditions NHL, NHL, Relapsed, Adult
Enrollment 90 participants
Start Date 2023-05-31
Primary Completion 2026-11 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2024-05-02